/ group-ii re e- tender for procurement of some drug items listed under table-a, for two years from the date of aoc , abacavir 600mg + lamivudine 300mg tabs , abacavir 60mg + lamivudine 30mg tabs , adenosine inj. u.s.p. 3 mg / ml in 2 ml. , benzyl benzoate application i.p 25% w / w-500 ml bot. , bupivacaine 0.5% inj - 20ml vial , cabergoline tab 0.5mg , carmustine inj. 100mg / vial , cephalexin tab / cap 125 mg. , cetuximab inj. 100mg ( 5mg / ml ) / - 20ml vial , cetuximab inj. 500 mg ( 5mg / ml ) / 100ml vial , clofazimine 100 mg tab. , clofazimine capsule 50mg , daclatasvir 60 mg tab. , darunavir 600 mg tabs , decitabine inj 50 mg , desflurence inhalation agent 240 ml , dexamithasone tab. i.p. 0.5 mg , ethionamide 125 mg tab. , fibrin sealent with fast & slow setting of thrombin 1ml , finasteride tab 5mg , fludarabine inj. - 50mg / 5ml , flurourocil inj. i.p. 250mg. in 5ml. amp. , halazone tablet for solution u.s.p. 4mg , human hepatitis b immunoglobulin inj. 200 iu volume in 0.5 ml or 1 ml vial / pfs , ibrutinib 140 mg cap. , infliximab inj. 100mg / vial , itraconazole 100 mg cap. , ivermectin 6mg tab. , leuprolide depot inj. 22.5 mg / vial , linezolid infusion 600 mg / 300ml , medroxy progesterone acetate 10 mg tab. , melphalan hcl inj. 50 mg ( powder ) , methotrexate tab 15 mg , misoprostol tab. 100 mcg , octreotide ( lar ) as free peptide 30mg inj. , penicillamine 250 mg. cap. , phenobarbitone 60 mg tab. , plerixafor inj 24mg / 1.2ml per vial , polymixin b sulfate inj. 5, 00, 000 units / vial , pomalidomide 2mg tab / cap , pyridostigmine tab 30 mg , rifabutin 150mg cap. , rifampicin capsule / tablet i.p.450mg , rifampicin capsule i.p. 150 mg. , ritonavir 100 mg tab. , sevelamer hydrocloride tab 400mg , sodium chloride inj 0.45% with dextrose 5% polypropelene bottle in ffs technology , succinylated polygelline , succinylcholine chloride inj. 50mg. / ml. , tetanus toxoid inj. ( absorbed ) 0.5ml amp. single dose , tinidazole tab ip 500 mg , triptorelin 11.25 mg inj. , vecuronium bromide inj. 2mg / ml 2ml vial , zidovudine 60 mg + lamivudine 30mg tabs , important note: 1. all prospective bidders are requested to quote the rate in boq as per accounting unit & item specification as mentioned in the table-a. wrong quoting of the rate in boq will be dealt with as per penal provisions of the t&c of the tender. 2. quality of the product supplied, may be ascertained by testing / physical examination by the experts at any stage of the tender period. 3. the prospective bidders of the said tender are requested to make a declaration in affidavit under annexure vi ( b ) in case of sole manufacturer / importer ( i.e. proprietary in nature ) . 4. if the item ( s ) under sole manufacturer / importer is ( are ) proprietary in nature, quarterly intimation is solicited from the approved bidders positively regarding the status of their item ( s ) proprietary in nature, otherwise their item ( s ) will be blocked in the smis. 5. in case of tie bid, decision will be taken by the tia as per g.o. no. 2320-f ( y ) , dated 07.06.2022 issued from finance department audit branch ( group t ) .